Monte Rosa Therapeutics, Inc. (GLUE) Total liabilities 2023–2025
Monte Rosa Therapeutics, Inc. (GLUE) total liabilities at each fiscal year-end, per SEC filings.
$215.6MFY2025 · since FY2023: $124.5M → $215.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $215.6M | -0.1% |
| FY2024 | $215.8M | +73.3% |
| FY2023 | $124.5M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More GLUE financial trends
GLUE RevenueGLUE Net incomeGLUE Net marginGLUE Gross profitGLUE Gross marginGLUE Operating incomeGLUE Operating marginGLUE Operating cash flowGLUE Free cash flowGLUE Capital expendituresGLUE Return on equityGLUE Stock buybacksGLUE Dividends paidGLUE Total assetsGLUE Shareholders’ equityGLUE overview →